Galderma Laboratories Inc.

Galderma Research & Development

Galderma Research & Development Snc

Christian Loesche

Michael Graeber

Matthew James Leoni

Philip Freidenreich

Michel Poncet

Denis Gross

Yin-sang Liu

Marie-line Abou-Chacra Vernet

Jack A DeJovin

Isabelle Jean DeJovin

Marie-Line Abou Chacra Vernet

Yin-Sang Liu

Yin Liu

Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier.

Methods and compositions for safe and effective treatment of erythema

Improved methods and compositions for safe and effective treatment of telangiectasia or a symptom associated with telangiectasia in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier.

Methods and compositions for safe and effective treatment of telangiectasia

Acne lesions, whether of inflammatory and/or non-inflammatory type, are simultaneously or sequentially treated and their number reduced, via daily topical regimen, with the combination or association of adapalene or pharmaceutically acceptable salt thereof and benzoyl peroxide (BPO).

Combination/association of adapalene and benzoyl peroxide for treating acne lesions

Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one &#x3b1;-adrenergic receptor agonist and a pharmaceutically acceptable carrier.

Methods and compositions for treating or preventing erythema

Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.4% to about 0.6% by weight of brimonidine and a pharmaceutically acceptable carrier.

Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO.

Growing community of inventors

Valbonne, France

Christian Loesche